Login
$BDSX
$9.00 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Scott Hutton Also a director
President & CEO
Title from the Form 4 dated Feb 20, 2026
Not stated Not stated Not stated $2,238,470
Robin Harper Cowie
Chief Financial Officer
46 Since 2017
9 years
2011 $962,001
Kieran O’Kane
Chief Commercial Officer
48 Since 2020
6 years
2018 $1,007,292

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
5 of 5
stated in the proxy; 2 not stated
Average tenure
8.3 years
from year joined
CEO also chairs the board
No
John Patience
Director On board Independent Committees Other public boards Pay Source
John Patience
2008
18 years
Independent
Compensation Committee
Accelerate Diagnostics, Inc. Not stated
Scott Hutton
2020
6 years
Not stated None stated Eximis Surgical, Inc. Paid as CEO
Jean Franchi
2020
6 years
Not stated
Audit Committee · Chair
VectorY Therapeutics Not stated
Hany Massarany
2020
6 years
Independent
Compensation Committee · Chair
Accelerate Diagnostics Not stated
Jon Faiz Kayyem
2021
5 years
Independent
Compensation Committee
Inhibrix Biosciences, Inc. Not stated
Lawrence T. Kennedy, Jr.
2023
3 years
Independent
Nominating and Corporate Governance Committee
Healthcare for Kids, Caliber Healthcare Solutions, Revolution 4.0, Health Carousel Not stated
Matthew Strobeck
2012
14 years
Independent
Nominating and Corporate Governance Committee · Chair
QuidelOrtho Corporation, Accelerate Diagnostics, Monteris Medical Corporation Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 9, 2026
members of our board of directors
members of our board of directors who invested in the consortium
$46.00 per share
2024

Purchase of Series A Preferred Stock in the April 2024 private placement at $46.00 per share

With the Company Open in proxy
Chief Executive Officer, Chief Financial Officer and Chief Commercial Officer
members of the Company's management team, including our Chief Executive Officer, Chief Financial Officer and Chief Commercial Officer
$46.00 per share
2024

Purchase of Series A Preferred Stock in the April 2024 private placement at $46.00 per share

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support